Dismiss Notice
Links from our daily front page news are now being fed to this board. If you want to comment on any of the news articles, you can now do so there.

Xarelto vs Eliquis - Pfizer/BMS win....

Discussion in 'Ortho-McNeil' started by Anonymous, Jun 23, 2011 at 3:06 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    When several drugmakers are developing similar new drugs, there's always a lot of talk about which one will reach the market first. In the case of clot-busting drugs to compete with the old standby warfarin, Boehringer Ingelheim won that race with Pradaxa. Since then, it's been a race for second-to-market status between Pfizer and Bristol-Myers Squibb's candidate apixaban--branded as Eliquis--and Bayer's Xarelto, approved in Europe but waiting for the FDA nod.

    But now, new data on the Pfizer/BMS drug is throwing the contest into disarray. Pradaxa's first-to-market score may just be a token prize. That's because Eliquis, the yet-to-be-approved drug, aced a late-stage trial, performing far beyond analysts' expectations. The drug was more effective at preventing strokes than warfarin--and safer, too. That means Eliquis patients were less likely to develop bleeding problems than those using the older drug.

    As Forbes notes, Eliquis had been considered the third-ranking drug in the warfarin-replacement crowd. Now, it might just find itself in first place. Boehringer's Pradaxa did perform better than warfarin, but the study wasn't totally blind, so the FDA didn't allow the company to claim superiority for its product. If the FDA allows Pfizer and BMS to slap a superiority note on Eliquis, their drug could gain a major edge. "At first blush, it's a home run for apixaban. It looks better than the other two drugs," Barclays Capital analyst Tony Butler told Reuters.

    Meanwhile, the data on Bayer's Xarelto shows the drug is equivalent to--not better than--warfarin on safety and efficacy, Forbes notes. But it's a once-a-day drug. So, it might have a dosing advantage; but then again, the lack of superiority could give the edge to Eliquis. Investors were worried enough that Bayer's stock fell by as much as 5 percent.

    But we'll only know more once the new study's details are unveiled at an upcoming conference. The early data is just headline info, not nitty-gritty stuff.
  2. Anonymous

    Anonymous Guest

  3. Anonymous

    Anonymous Guest

    Apixaban will compete against Boehringer Ingelheim GmbH’s Pradaxa, approved last year, in the contest to replace the half- century-old drug warfarin, a sensitive medicine that requires regular laboratory tests to ensure patients get the proper dose. Xarelto, another rival from Bayer AG of Leverkusen, Germany, and New Brunswick, New Jersey-based Johnson & Johnson (JNJ), is awaiting U.S. approval.
    “Since apixaban looks very likely to be the only blood thinner with superior efficacy and safety, we think it could take as much as 50 percent” of the market for atrial fibrillation, Schoenebaum wrote. “At peak that represents worldwide sales of $3.5 billion” in the heart condition alone, and increase from a $1.4 billion estimate before yesterday’s data, he wrote.
  4. Anonymous

    Anonymous Guest


    moles are implanted to make those statements to get action on the stock market.
    means zip.
    xarelto and eliquis will battle for runner up, pradaxa will remain king.
  5. Anonymous

    Anonymous Guest

    You guys are so fucked

    Most hospitals will choose less expensive alternatives. Patient care is #10 in importance when making real formulary decisions.

    All insurance plans will make it 3rd tier with coumadin failure before they cover it. Good luck. Days of J&J pharma are over....and I'm so happpppppppppyyyyyy.
  6. Anonymous

    Anonymous Guest

    How could you be so happpppppppppppyyyyy after your posting ?????????
    [[[--You can't build happiness on other people's unhappiness.--]]]
  7. Anonymous

    Anonymous Guest

    your a genious.. now what does a coumadine failure look like? think about it
  8. Anonymous

    Anonymous Guest

    Only true if there is no superiority data of one drug against another. The game changes on superior data, then evidence based protocols take into effect. If the guidelines support superiority of one drug over another then that drug will assume first line positioning. Its becomes very difficult, actually can put a hospital in a legal liability position, to deny a superior drug for patient care. Especially a medicine that is considered life sustaining. CMS has implemented quality of care as one of the priorities for core measures. You don't spend much time in the hospital environment making the statement you just made.
  9. Anonymous

    Anonymous Guest

    This poster is too stupid to chew gum. Rarely is the first product in a stale market the ultimate winner. Usually it's the second or third that hit market.

    One problem for all this: Medicare will dominate the payment for anticoagulants.

    That said, the Federal Gov't is running 1.5 trillion $ deficits, the economy is rolling over into decline, the stock market's tail wind of money "printing" by the central bank is over and, given its effect on gasoline prices (spiked higher) not to be redone. The national debt is rising at an exponential rate (I know, few of you understand mathematics.)

    Medicare, Medicaid, and Social Security already consume almost all tax receipts, plus you have a trillion dollars of war being "fought" each year with no end in sight.

    If you people think Medicare is going to be business as usual in coming years, I have a bridge or some Florida swamp land to sell you.

    The days of honey and joy are OVER. I enjoyed the $100K-plus and the company car while it lasted, but I could see the future and saved a lot of that. Those of you who bought the McMansion and think this gig has legs are truly fools, and you know what they say about a fool and his money....
  10. Anonymous

    Anonymous Guest

    MOST do not get it. They believe/think the future will be buisness as usual. You an I know it will not. Best of luck 'head north'.

  11. Anonymous

    Anonymous Guest

    The thing you have to keep in mind is:
    1. Everyone must compare to coumadin to just line up for the race.
    2. One study does not make the final call.
    Do you remember apixaban had a study D/C'd due to excessive bleeds?
    CV docs will take that into factor.
    3. The real decisions will be made once we begin head to head vs. the other Xa's- Riva vs. apix et al. That is when where the war will be decided. Those studies are still years away from announcement.

    It was the same way w/ the statin's. It was Mevacor/Zocor vs. Pravachol. There was h to h studies then the big survival study in 4S. That gave Z the big advantage. Then, the monster Lipitor came alone and Cleaned EVERYONE's clock.

    Also, you can't factor out the Medicare section. It ain't business as usual and $$$ by 3rd party payors could still really screw us.
  12. Anonymous

    Anonymous Guest

  13. Anonymous

    Anonymous Guest

    Pradaxa > Xarelto > Eliquis = who will win?

    Clinical studies are not real life. Average drug has 40% compliance thus a twice a day (BID) drug vs. once a day drug (QD) the QD drug will perform better. There will never be head to head studies, but BID dosed drug with average compliance will result in sub therapeutic levels and be less effective. Eliquis has a long way to go and yet unknown analysis have to be completed. Only time will tell who will be the leader 12-31-2012!
  14. Anonymous

    Anonymous Guest

    FYI. Your number 2. Do you remember apixaban had a study D/C'd due to excessive bleed? You obviously don't know that Xarelto also had a study problem due to excessive bleeds. Hum, I wonder if it has to do with the class that both drugs are in? Hum, if you had read the results of both data, heavily reported, you would know what the class has to do with excessive bleeds. I am guessing you are not going to be selling Xarelto, because not knowing impt. info. about this class of drugs that was widely reported would make you not very qualified to sell this product. You should read the data about apixaban first before you make comments. Happens all the time. They're everywhere.
  15. Anonymous

    Anonymous Guest

    Re: Pradaxa > Xarelto > Eliquis = who will win?

    Never have seen the data you are referring to regarding QD vs. BID adherence in 15+ years. Or does making things up apply as clinical data these days to some in the pharma industry. Cite your sources. Then determine what it means to have superior data vs. comparable data for these new drugs. You should be able to determine alot after that.